- Abstract:
-
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. Al...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
- Files:
-
-
(pdf, 270.3KB)
-
(pdf, 31.1KB)
-
- Publisher copy:
- 10.1111/bjh.14898
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Wiley Publisher's website
- Journal:
- British Journal of Haematology Journal website
- Volume:
- 179
- Issue:
- 3
- Pages:
- 471-479
- Publication date:
- 2017-08-31
- Acceptance date:
- 2017-07-18
- DOI:
- EISSN:
-
1365-2141
- ISSN:
-
0007-1048
- Pubs id:
-
pubs:725854
- URN:
-
uri:db8a45c6-e6e1-4263-aba2-c8c8d3b8abc2
- UUID:
-
uuid:db8a45c6-e6e1-4263-aba2-c8c8d3b8abc2
- Local pid:
- pubs:725854
- Language:
- English
- Keywords:
- Copyright holder:
- John Wiley & Sons Ltd
- Copyright date:
- 2017
- Notes:
-
© 2017 John Wiley & Sons Ltd. This is the author accepted manuscript following peer review version of the article. The final version is
available online from Wiley at: https://doi.org/10.1111/bjh.14898
Note: an erratum exists for this article, originally published and available at: https://doi.org/10.1111/bjh.15103
Journal article
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Julian Starmer-Smith lymphoma fund
More from this funder
National Institute for Health Research Biomedical Research Centre Programme
More from this funder
Bibliographic Details
Item Description
Terms of use
If you are the owner of this record, you can report an update to it here: Report update to this record